Perspectives on the Women's Health Initiative trial of hormone replacement therapy

Obstetrics and Gynecology

Volumn 100, Issue 6, 2002, Pages 1344-1353

  Grimes, David A ^a,b   Lobo, Rogerio A ^a,b  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b Columbia Univ Coll of Phys/Surg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CONJUGATED ESTROGEN; GESTAGEN; LIPID; MEDROXYPROGESTERONE ACETATE; PLACEBO; RALOXIFENE; RISEDRONIC ACID;

BLOOD PRESSURE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; EXERCISE; FRAGILITY FRACTURE; HEALTH; HEART DISEASE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SMOKING CESSATION; SYMPTOMATOLOGY; WEIGHT;

EID: 0036898962     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(02)02503-6     Document Type: Article

References (86)

1. Risks and benefits of estrogen plus progestin in healthy postmenopausal women Principal results from the Women's Health Initiative randomized controlled trial . JAMA. 288:2002;321-333.
2. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., Allan J.D. Postmenopausal hormone replacement therapy Scientific review . JAMA. 288:2002;872-881.
3. Brown D. First, do the trials. Then, do no harm. August 4, 2002;Washington Post. B1.
4. Barrett-Connor E., Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health. 19:1998;55-72.
5. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 273:1995;199-208.
6. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 340:1999;1801-1811.
7. Adams M.R., Washburn S.A., Wagner J.D., Williams J.K., Clarkson T.B. Arterial changes Estrogen deficiency and effects of hormone replacement . Lobo R.A. Treatment of the Postmenopausal Woman Basic and Clinical Aspects . 2nd Ed:1999;377-384 Lippincott Williams & Wilkins, Philadelphia.
8. Mosca L., Collins P., Herrington D.M., Mendelsohn M.E., Pasternak R.C., Robertson R.M., et al. Hormone replacement therapy and cardiovascular disease A statement for healthcare professionals from the American Heart Association . Circulation. 104:2001;499-503.
9. Mendelsohn M.E., Karas R.H. The time has come to stop letting the HERS tale wag the dogma. Circulation. 104:2001;2256-2259.
10. Henderson B.E., Paganini-Hill A., Ross R.K. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 151:1991;75-78.
11. Ettinger B., Friedman G.D., Bush T., Quesenberry C.P. Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 87:1996;6-12.
12. Grodstein F., Stampfer M.J., Colditz G.A., Willett W.C., Manson J.E., Joffe M., et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 336:1997;1769-1775.
13. Stampfer M.J., Colditz G.A., Willett W.C., Manson J.E., Rosner B., Speizer F.E., et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med. 325:1991;756-762.
14. Clarkson T.B. The new conundrum Do estrogens have any cardiovascular benefits? Int J Fertil Womens Med. 47:2002;61-68.
15. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613.
16. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 343:2000;522-529.
17. Herrington D.M., Klein K.P. Cardiovascular trials of estrogen replacement therapy. Ann N Y Acad Sci. 949:2001;153-162.
18. Campisi R., Nathan L., Pampaloni M.H., Schoder H., Sayre J.W., Chaudhuri G., et al. Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration. Circulation. 105:2002;425-430.
19. Reis S.E., Gloth S.T., Blumenthal R.S., Resar J.R., Zacur H.A., Gerstenblith G., et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 89:1994;52-60.
20. Post W.S., Goldschmidt-Clermont P.J., Wilhide C.C., Heldman A.W., Sussman M.S., Ouyang P., et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res. 43:1999;985-991.
21. Fleming T.R., DeMets D.L. Surrogate end points in clinical trials Are we being misled? Ann Intern Med. 125:1996;605-613.
22. Dubey R.K., Jackson E.K. Estrogen-induced cardiorenal protection Potential cellular, biochemical, and molecular mechanisms . Am J Physiol Renal Physiol. 280:2001;F365-388.
23. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy Heart and Estrogen/Progestin Replacement Study follow-up (HERS II) . JAMA. 288:2002;49-57.
24. Baggett B., Nash H.A. Effects of contraceptive steroids on serum lipoproteins and cardiovascular disease scrutinized at workshop in Bethesda. Contraception. 21:1980;115-120.
25. Croft P., Hannaford P. Risk factors for acute myocardial infarction in women. BMJ. 298:1989;674.
26. Riggs B.L., Hodgson S.F., O'Fallon W.M., Chao E.Y., Wahner H.W., Muhs J.M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 322:1990;802-809.
27. Pak C.Y., Sakhaee K., Adams-Huet B., Piziak V., Peterson R.D., Poindexter J.R. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med. 123:1995;401-408.
28. Humphrey L.L., Chan B.K., Sox H.C. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 137:2002;273-284.
29. Rossouw J.E. Debate The potential role of estrogen in the prevention of heart disease in women after menopause . Curr Control Trials Cardiovasc Med. 1:2000;135-138.
30. Petitti D.B. Hormone replacement therapy and heart disease prevention Experimentation trumps observation . JAMA. 280:1998;650-652.
31. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 115:1991;455-456.
32. Barrett-Connor E., Wingard D.L., Criqui M.H. Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited. JAMA. 261:1989;2095-2100.
33. Matthews K.A., Kuller L.H., Wing R.R., Meilahn E.N., Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 143:1996;971-978.
34. Limacher M.C. Hormones and heart disease What we thought, what we have learned, what we still need to know . Trans Am Clin Climatol Assoc. 113:2002;31-41.
35. Santoro N.F., Col N.F., Eckman M.H., Wong J.B., Pauker S.G., Cauley J.A., et al. Therapeutic controversy Hormone replacement therapy - where are we going? J Clin Endocrinol Metab. 84:1999;1798-1812.
36. Sturgeon S.R., Schairer C., Brinton L.A., Pearson T., Hoover R.N. Evidence of a healthy estrogen user survivor effect. Epidemiology. 6:1995;227-231.
37. Chalmers T.C., Celano P., Sacks H.S., Smith H. Jr. Bias in treatment assignment in controlled clinical trials. N Engl J Med. 309:1983;1358-1361.
38. Moher D., Schulz K.F., Altman D.G. The CONSORT statement Revised recommendations for improving the quality of reports of parallel-group randomised trials . Lancet. 357:2001;1191-1194.
39. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 19:1998;61-109.
40. Rossouw J.E. Estrogens for prevention of coronary heart disease. Putting the brakes on the bandwagon. Circulation. 94:1996;2982-2985.
41. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 15:1995;551-561.
42. Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann Intern Med. 135:2001;1-8.
43. Herrington D.M., Vittinghoff E., Lin F., Fong J., Harris F., Hunninghake D., et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 105:2002;2962-2967.
44. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
45. Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 348:1996;981-983.
46. Grodstein F., Stampfer M.J., Goldhaber S.Z., Manson J.E., Colditz G.A., Speizer F.E., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987.
47. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 133:2000;933-941.
48. Ross R.K., Pike M.C., Henderson B.E., Mack T.M., Lobo R.A. Stroke prevention and oestrogen replacement therapy. Lancet. 1:1989;505.
49. Finucane F.F., Madans J.H., Bush T.L., Wolf P.H., Kleinman J.C. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med. 153:1993;73-79.
50. Dupont W.D., Page D.L. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med. 151:1991;67-72.
51. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332:1995;1589-1593.
52. Breast cancer and hormone replacement therapy Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer . Lancet. 350:1997;1047-1059.
53. Nanda K., Bastian L.A., Schulz K. Hormone replacement therapy and the risk of death from breast cancer A systematic review . Am J Obstet Gynecol. 186:2002;325-334.
54. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:2000;485-491.
55. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk Estrogen versus estrogen plus progestin . J Natl Cancer Inst. 92:2000;328-332.
56. Li C.I., Weiss N.S., Stanford J.L., Daling J.R. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer. 88:2000;2570-2577.
57. Marcus R., Wong M., Heath H. 3rd, Stock J.L. Antiresorptive treatment of postmenopausal osteoporosis Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint . Endocr Rev. 23:2002;16-37.
58. Torgerson D.J., Bell-Syer S.E. Hormone replacement therapy and prevention of nonvertebral fractures A meta-analysis of randomized trials . JAMA. 285:2001;2891-2897.
59. Lufkin E.G., Riggs B.L. Three-year follow-up on effects of transdermal estrogen. Ann Intern Med. 125:1996;77.
60. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet. 359:2002;2018-2026.
61. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators . JAMA. 282:1999;637-645.
62. MacLennan S.C., MacLennan A.H., Ryan P. Colorectal cancer and oestrogen replacement therapy. A meta-analysis of epidemiological studies. Med J Aust. 162:1995;491-493.
63. Nanda K., Bastian L.A., Hasselblad V., Simel D.L. Hormone replacement therapy and the risk of colorectal cancer A meta-analysis . Obstet Gynecol. 93:1999;880-888.
64. Freedman L., Anderson G., Kipnis V., Prentice R., Wang C.Y., Rossouw J., et al. Approached to monitoring the results of long-term disease prevention trials Examples from the Women's Health Initiative . Control Clin Trials. 17:1996;509-525.
65. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics. 35:1979;549-556.
66. Pocock S.J. When to stop a clinical trial. BMJ. 305:1992;235-240.
67. Schulz K.F., Grimes D.A. Sample size slippages in randomised trials Exclusions and the lost and wayward . Lancet. 359:2002;781-785.
68. Schulz K.F., Grimes D.A. Blinding in randomised trials Hiding who got what . Lancet. 359:2002;696-700.
69. Shaywitz S.E., Shaywitz B.A., Pugh K.R., Fulbright R.K., Skudlarski P., Mencl W.E., et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA. 281:1999;1197-1202.
70. Cela V., Naftolin F. Clinical effects of sex steroids on the brain. Lobo R.A. Treatment of the Postmenopausal Woman Basic and Clinical Aspects . 2nd Ed:1999;247-262 Lippincott Williams & Wilkins, Philadelphia.
71. McEwen B.S., Alves S.E., Bulloch K., Weiland N.G. Ovarian steroids and the brain Implications for cognition and aging . Neurology. 48:1997;S8-15.
72. LeBlanc E.S., Janowsky J., Chan B.K., Nelson H.D. Hormone replacement therapy and cognition Systematic review and meta-analysis . JAMA. 285:2001;1489-1499.
73. Henderson V.W. The role of sex steroids in Alzheimer's disease: Prevention and treatment. Lobo R.A. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. 2nd Ed:1999;269-276 Lippincott Williams & Wilkins, Philadelphia.
74. Enserink M. Epidemiology. Despite safety concerns, U.K. hormone study to proceed. Science. 297:2002;492.
75. Enserink M. Women's health. U.K. hormone trial to pause for review. Science. 297:2002;755-757.
76. MacLennan A., Lester S., Moore V. Oral oestrogen replace-ment therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 1:2001;CD002978.
77. Lobo R.A., Whitehead M.I. Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? Climacteric. 4:2001;110-119.
78. Utian W.H., Shoupe D., Bachmann G., Pinkerton J.V., Pickar J.H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 75:2001;1065-1079.
79. Grady D. A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA. 287:2002;2130-2137.
80. Davis S.R. Phytoestrogen therapy for menopausal symptoms? BMJ. 323:2001;354-355.
81. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation . JAMA. 281:1999;2189-2197.
82. Nelson H.D. Assessing benefits and harms of hormone replacement therapy Clinical applications . JAMA. 288:2002;882-884.
83. Pearson T.A., Blair S.N., Daniels S.R., Eckel R.H., Fair J.M., Fortmann S.P., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke 2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee . Circulation. 106:2002;388-391.
84. Heinemann D.F. Osteoporosis. An overview of the National Osteoporosis Foundation clinical practice guide. Geriatrics. 55:2000;31-36. 39.
85. Guide to Clinical Preventive Services. 2nd Ed:1996;Williams & Wilkins, Baltimore.
86. Meyer V.F. The medicalization of menopause Critique and consequences . Int J Health Serv. 31:2001;769-792.